Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

about

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q47568290

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

@en

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

@nl

type

Item

label

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

@en

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

@nl

prefLabel

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

@en

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

@nl

P1476

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

@en

P2093

Arti Hurria

http://www.w3.org/2001/XMLSchema#string

Bean Anyang

http://www.w3.org/2001/XMLSchema#string

George Somlo

http://www.w3.org/2001/XMLSchema#string

Kyu-Pyo Kim

http://www.w3.org/2001/XMLSchema#string

Lixin Yang

http://www.w3.org/2001/XMLSchema#string

Suzette Blanchard

http://www.w3.org/2001/XMLSchema#string

Thehang Luu

http://www.w3.org/2001/XMLSchema#string

Yun Yen

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer treatment and survivorship statistics, 2012

A modified toxicity probability interval method for dose-finding trials.

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

Histone deacetylases and cancer: causes and therapies.

P2888

s10549-017-4516-x

P304

469-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-017-4516-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P50

Jan H Beumer

P577

2017-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28956187

http://www.w3.org/2001/XMLSchema#string